Anavex Life Sciences (NASDAQ:AVXL – Get Free Report) and Aligos Therapeutics (NASDAQ:ALGS – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.
Volatility and Risk
Anavex Life Sciences has a beta of 0.73, suggesting that its share price is 27% less volatile than the S&P 500. Comparatively, Aligos Therapeutics has a beta of 2.73, suggesting that its share price is 173% more volatile than the S&P 500.
Profitability
This table compares Anavex Life Sciences and Aligos Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anavex Life Sciences | N/A | -30.64% | -28.23% |
| Aligos Therapeutics | -1,283.19% | -114.34% | -64.58% |
Analyst Ratings
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anavex Life Sciences | 0 | 0 | 2 | 1 | 3.33 |
| Aligos Therapeutics | 0 | 0 | 1 | 0 | 3.00 |
Anavex Life Sciences currently has a consensus target price of $43.00, indicating a potential upside of 407.67%. Aligos Therapeutics has a consensus target price of $75.00, indicating a potential upside of 95.57%. Given Anavex Life Sciences’ stronger consensus rating and higher probable upside, research analysts plainly believe Anavex Life Sciences is more favorable than Aligos Therapeutics.
Insider & Institutional Ownership
31.5% of Anavex Life Sciences shares are owned by institutional investors. Comparatively, 60.4% of Aligos Therapeutics shares are owned by institutional investors. 11.0% of Anavex Life Sciences shares are owned by insiders. Comparatively, 8.8% of Aligos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Earnings and Valuation
This table compares Anavex Life Sciences and Aligos Therapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Anavex Life Sciences | N/A | N/A | -$47.51 million | ($0.50) | -16.94 |
| Aligos Therapeutics | $6.00 million | 22.94 | -$87.68 million | ($13.32) | -2.88 |
Anavex Life Sciences has higher earnings, but lower revenue than Aligos Therapeutics. Anavex Life Sciences is trading at a lower price-to-earnings ratio than Aligos Therapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Anavex Life Sciences beats Aligos Therapeutics on 10 of the 14 factors compared between the two stocks.
About Anavex Life Sciences
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.
About Aligos Therapeutics
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Receive News & Ratings for Anavex Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.
